In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs

被引:23
作者
Tay, S. T. [1 ]
Haryanty, T. Tanty
Ng, K. P.
Rohani, M. Y.
Hamimah, H.
机构
[1] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur 50603, Malaysia
[2] Inst Med Res Jalan Pahang, Bacteriol Div, Kuala Lumpur, Malaysia
关键词
Cryptococcus neoformans; C; gattii; antifungal drugs; Etest method;
D O I
10.1111/j.1439-0507.2006.01242.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The in vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and C . gattii to five antifungal drugs (amphotericin B, flucytosine, fluconazole, itraconazole and ketoconazole) were determined using the Etest method. None of the Malaysian isolates was resistant to amphotericin B and ketoconazole. Isolates resistant to flucytosine, fluconazole and itraconazole were observed in this study. Minimum inhibition concentrations (MICs) of >= 32 mu g ml(-1) against flucytosine, >= 64 mu g ml(-1) against fluconazole and >= 1 mu g ml(-1)against itraconazole were noted in four (8.3%), two (4.2%) and one (2.1%) isolates respectively. There was no significant difference in the MICs for both Cryptococcus species (P > 0.05), indicating that C. gattii was as susceptible as var. grubii to all the antifungal drugs tested. No significant difference in the MICs for both Cryptococcus species collected from 1980 to 1990 and 2002 to 2004 were observed (P > 0.05).
引用
收藏
页码:324 / 330
页数:7
相关论文
共 41 条
[1]   Antifungal susceptibilities of Cryptococcus neoformans [J].
Archibald, LK ;
Tuohy, MJ ;
Wilson, DA ;
Nwanyanwu, O ;
Kazembe, PN ;
Tansuphasawadikul, S ;
Eampokalap, B ;
Chaovavanich, A ;
Reller, LB ;
Jarvis, WR ;
Hall, GS ;
Procop, GW .
EMERGING INFECTIOUS DISEASES, 2004, 10 (01) :143-145
[2]   The hidden danger of primary fluconazole prophylaxis for patients with AIDS [J].
Berg, J ;
Clancy, CJ ;
Nguyen, MH .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :186-187
[3]   Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans [J].
Boekhout, T ;
Theelen, B ;
Diaz, M ;
Fell, JW ;
Hop, WCJ ;
Abeln, ECA ;
Dromer, F ;
Meyer, W .
MICROBIOLOGY-UK, 2001, 147 :891-907
[4]   Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States:: 1992 to 1994 and 1996 to 1998 [J].
Brandt, ME ;
Pfaller, MA ;
Hajjeh, RA ;
Hamill, RJ ;
Pappas, PG ;
Reingold, AL ;
Rimland, D ;
Warnock, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3065-3069
[5]   Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela [J].
Calvo, BM ;
Colombo, AL ;
Fischman, O ;
Santiago, A ;
Thompson, L ;
Lazera, M ;
Telles, F ;
Fukushima, K ;
Nishimura, K ;
Tanaka, R ;
Myiajy, M ;
Moretti-Branchini, ML .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (06) :2348-2350
[6]   In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia [J].
Chandenier, J ;
Adou-Bryn, KD ;
Douchet, C ;
Sar, B ;
Kombila, M ;
Swinne, D ;
Thérizol-Ferly, M ;
Buisson, Y ;
Richard-Lenoble, D .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (06) :506-508
[7]  
Chang WN, 2004, JPN J INFECT DIS, V57, P113
[8]   Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan [J].
Chen, YC ;
Chang, SC ;
Shih, CC ;
Hung, CC ;
Luh, KT ;
Pan, YS ;
Hsieh, WC .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (03) :175-183
[9]  
Chin C S, 1989, Med J Malaysia, V44, P194
[10]  
COMO JA, 1994, NEW ENGL J MED, V330, P263, DOI 10.1056/NEJM199401273300407